Fig. 4From: Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational studyMean HCRU cost per patient in both populations (pre- versus post-mepolizumab)Includes costs indicated in Table 3 (PSP population) and Table 4 (provincial drug coverage subset population)$CAD, Canadian dollars; HCRU, healthcare resource utilization; PSP, patient support programBack to article page